BioGend Therapeutics Co., Ltd. (TPEX: 6733)

Market Cap	4.52B
Revenue (ttm)	156.64M
Net Income (ttm)	-109.93M
Shares Out	124.26M
EPS (ttm)	-0.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,770
Open	36.20
Previous Close	36.50
Day's Range	36.15 - 36.75
52-Week Range	31.40 - 42.85
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About BioGend Therapeutics

BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was founded in 2016 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6733

Financial Performance

In 2023, BioGend Therapeutics's revenue was 109.91 million, an increase of 249.51% compared to the previous year's 31.45 million. Losses were -156.33 million, -15.25% less than in 2022.